These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 33658933

  • 1. Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sun Y, Yang Y, Wang Z, Jiang F, Chen Z, Wang Z.
    Front Pharmacol; 2020; 11():589146. PubMed ID: 33658933
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 6. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 7. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S, Li X, Wang J, Wang T, Xu Z, Gao H, Chen G.
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [Abstract] [Full Text] [Related]

  • 8. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug 24; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 10. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul 24; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2014 Jul 26; (7):CD009333. PubMed ID: 25062935
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
    Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K.
    Mult Scler Relat Disord; 2023 Mar 26; 71():104551. PubMed ID: 36791623
    [Abstract] [Full Text] [Related]

  • 13. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun 26; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 14. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B, Zierhut ML, Kracker H, Keenan A, Sidorenko T.
    Mult Scler Relat Disord; 2022 Aug 26; 64():103908. PubMed ID: 35803162
    [Abstract] [Full Text] [Related]

  • 15. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Aug 26; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 16. Rituximab for relapsing-remitting multiple sclerosis.
    He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.
    Cochrane Database Syst Rev; 2013 Dec 06; (12):CD009130. PubMed ID: 24310855
    [Abstract] [Full Text] [Related]

  • 17. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec 06; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 18. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.
    Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler AM, Lampl M, Linker RA.
    Front Neurol; 2022 Dec 06; 13():913616. PubMed ID: 35832177
    [Abstract] [Full Text] [Related]

  • 19. Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
    Jiang T, Ziemssen T, Wray S, Shen C, Söderbärg K, Lewin JB, Božin I, Freedman MS.
    CNS Drugs; 2023 May 06; 37(5):441-452. PubMed ID: 37155132
    [Abstract] [Full Text] [Related]

  • 20. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
    Long M, Cross R, Calkwood J, Pondel M, Pai A, Ahmad H, Charles L, Elegbe A, Petersen A, Sheffield J, Javed A, Wolf D.
    Am J Gastroenterol; 2021 Dec 01; 116(Suppl 1):S9-S10. PubMed ID: 37461957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.